Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Straggler Novavax Still Hopes To Hit Paydirt With Combo Vaccine

Executive Summary

The company announced early data for a combination vaccine against SARS-CoV-2 and influenza, which could provide a revenue opportunity of $2bn.

You may also be interested in...



Sanofi/GSK Next-Generation COVID-19 Vaccine Shows Promise As Booster

Phase III data from two studies of the adjuvanted recombinant vaccine candidate showed increases in neutralizing antibody titers against the original SARS-CoV-2 strain and variants of concern. 

US FDA To Publish Advisory Committee Timeline For COVID-19 Vaccine In Children Under 5

But CBER Director Peter Marks reiterated to Senators that EUAs cannot be granted for those children until applications are completed and submitted.

J&J Continues Signaling Aggressive M&A Approach To Drive Growth

Johnson & Johnson reported disappointing Q1 sales for its COVID-19 vaccine but called the Carvykti launch solid and discussed plans for further diversification of its multiple myeloma portfolio.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel